In the context of CML, it is known that CK2 interacts with BCR-ABL [34,35], and imatinib-resistant cells show sensitivity to CK2 inhibitor CX-4945 [22,26]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.